Concepts (240)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Retinal Detachment | 19 | 2019 | 83 | 3.070 |
Why?
|
| Vitrectomy | 18 | 2012 | 108 | 2.540 |
Why?
|
| Retinopathy of Prematurity | 11 | 2019 | 57 | 2.240 |
Why?
|
| Vitreous Body | 22 | 2008 | 106 | 2.040 |
Why?
|
| Triamcinolone Acetonide | 7 | 2008 | 37 | 1.660 |
Why?
|
| Retina | 11 | 2019 | 450 | 1.620 |
Why?
|
| Retinal Perforations | 6 | 2019 | 27 | 1.460 |
Why?
|
| Endophthalmitis | 8 | 2008 | 77 | 1.250 |
Why?
|
| Laser Coagulation | 6 | 2010 | 129 | 1.010 |
Why?
|
| Injections | 14 | 2008 | 155 | 0.980 |
Why?
|
| Lens, Crystalline | 7 | 2012 | 138 | 0.970 |
Why?
|
| Visual Acuity | 15 | 2019 | 816 | 0.970 |
Why?
|
| Glucocorticoids | 5 | 2007 | 382 | 0.910 |
Why?
|
| Electroretinography | 8 | 2010 | 114 | 0.830 |
Why?
|
| Anti-Infective Agents | 4 | 2008 | 265 | 0.580 |
Why?
|
| Refraction, Ocular | 2 | 2010 | 303 | 0.570 |
Why?
|
| Aza Compounds | 3 | 2006 | 15 | 0.550 |
Why?
|
| Angiogenesis Inhibitors | 3 | 2011 | 206 | 0.520 |
Why?
|
| Quinolines | 3 | 2006 | 98 | 0.520 |
Why?
|
| Antifungal Agents | 5 | 2010 | 288 | 0.520 |
Why?
|
| Fluoroquinolones | 5 | 2006 | 93 | 0.510 |
Why?
|
| Eye Infections, Fungal | 3 | 2008 | 77 | 0.500 |
Why?
|
| Gram-Positive Bacterial Infections | 3 | 2008 | 76 | 0.490 |
Why?
|
| Eye Infections, Bacterial | 3 | 2008 | 92 | 0.480 |
Why?
|
| Retinal Vein Occlusion | 2 | 2008 | 28 | 0.470 |
Why?
|
| Aqueous Humor | 6 | 2006 | 27 | 0.470 |
Why?
|
| Triazoles | 3 | 2004 | 138 | 0.460 |
Why?
|
| Retinal Diseases | 4 | 2006 | 172 | 0.410 |
Why?
|
| Fluorescein Angiography | 7 | 2019 | 138 | 0.410 |
Why?
|
| Pyrimidines | 3 | 2004 | 371 | 0.400 |
Why?
|
| Rabbits | 7 | 2008 | 718 | 0.380 |
Why?
|
| Myopia | 2 | 2010 | 192 | 0.370 |
Why?
|
| Macular Degeneration | 4 | 2008 | 115 | 0.370 |
Why?
|
| Retinal Hemorrhage | 3 | 2011 | 23 | 0.360 |
Why?
|
| Vitreous Detachment | 2 | 2007 | 15 | 0.340 |
Why?
|
| Preservatives, Pharmaceutical | 2 | 2007 | 14 | 0.340 |
Why?
|
| Suture Techniques | 2 | 2008 | 195 | 0.330 |
Why?
|
| Ectopia Lentis | 1 | 2008 | 12 | 0.300 |
Why?
|
| Postoperative Complications | 7 | 2009 | 3069 | 0.300 |
Why?
|
| Bacillus cereus | 1 | 2008 | 8 | 0.300 |
Why?
|
| Pneumonia, Pneumocystis | 1 | 2008 | 36 | 0.300 |
Why?
|
| Cryotherapy | 2 | 2006 | 22 | 0.290 |
Why?
|
| Chromatography, High Pressure Liquid | 6 | 2008 | 345 | 0.290 |
Why?
|
| Iris | 1 | 2008 | 65 | 0.290 |
Why?
|
| AIDS-Related Opportunistic Infections | 1 | 2008 | 136 | 0.280 |
Why?
|
| Retrospective Studies | 19 | 2019 | 16312 | 0.280 |
Why?
|
| Vascular Endothelial Growth Factor A | 3 | 2011 | 409 | 0.270 |
Why?
|
| Pharmaceutical Vehicles | 1 | 2006 | 1 | 0.270 |
Why?
|
| Retinal Neovascularization | 1 | 2006 | 14 | 0.270 |
Why?
|
| Benzyl Alcohol | 1 | 2006 | 2 | 0.270 |
Why?
|
| Lens Implantation, Intraocular | 2 | 2008 | 342 | 0.260 |
Why?
|
| Gestational Age | 7 | 2006 | 1160 | 0.260 |
Why?
|
| Tomography, Optical Coherence | 4 | 2017 | 522 | 0.260 |
Why?
|
| Telangiectasis | 1 | 2006 | 8 | 0.260 |
Why?
|
| Fovea Centralis | 1 | 2006 | 10 | 0.260 |
Why?
|
| Retinal Vessels | 2 | 2003 | 75 | 0.250 |
Why?
|
| Cat-Scratch Disease | 1 | 2005 | 33 | 0.240 |
Why?
|
| Antibodies, Monoclonal | 2 | 2008 | 1034 | 0.240 |
Why?
|
| Infant, Newborn | 11 | 2012 | 8196 | 0.230 |
Why?
|
| Male | 30 | 2019 | 61436 | 0.230 |
Why?
|
| Phacoemulsification | 2 | 2005 | 236 | 0.230 |
Why?
|
| Triamcinolone | 1 | 2004 | 14 | 0.220 |
Why?
|
| Treatment Outcome | 12 | 2012 | 12382 | 0.220 |
Why?
|
| Follow-Up Studies | 7 | 2012 | 5169 | 0.210 |
Why?
|
| Photochemotherapy | 1 | 2003 | 35 | 0.210 |
Why?
|
| Humans | 42 | 2019 | 125035 | 0.210 |
Why?
|
| Lenses, Intraocular | 1 | 2008 | 396 | 0.210 |
Why?
|
| Papilledema | 1 | 2003 | 78 | 0.200 |
Why?
|
| Infant, Very Low Birth Weight | 5 | 2006 | 172 | 0.200 |
Why?
|
| Aged | 15 | 2019 | 19859 | 0.200 |
Why?
|
| Anti-Bacterial Agents | 4 | 2008 | 2425 | 0.190 |
Why?
|
| Microbial Sensitivity Tests | 5 | 2006 | 796 | 0.190 |
Why?
|
| Choroid | 2 | 2017 | 39 | 0.190 |
Why?
|
| Female | 24 | 2019 | 66718 | 0.190 |
Why?
|
| Osmolar Concentration | 3 | 2008 | 176 | 0.180 |
Why?
|
| Mitosporic Fungi | 1 | 2001 | 9 | 0.180 |
Why?
|
| Eye Injuries, Penetrating | 1 | 2001 | 19 | 0.180 |
Why?
|
| Prednisolone | 1 | 2001 | 74 | 0.180 |
Why?
|
| Alcaligenes | 1 | 2000 | 3 | 0.170 |
Why?
|
| Propionibacterium acnes | 1 | 2000 | 12 | 0.170 |
Why?
|
| Biological Availability | 4 | 2006 | 137 | 0.170 |
Why?
|
| Retinal Artery Occlusion | 1 | 2000 | 16 | 0.170 |
Why?
|
| Disease Progression | 4 | 2019 | 2061 | 0.170 |
Why?
|
| Keratitis | 1 | 2001 | 116 | 0.170 |
Why?
|
| Purpura, Thrombotic Thrombocytopenic | 1 | 2000 | 53 | 0.170 |
Why?
|
| Pseudophakia | 1 | 2000 | 73 | 0.160 |
Why?
|
| Mycoses | 1 | 2001 | 118 | 0.160 |
Why?
|
| Gram-Negative Bacterial Infections | 1 | 2000 | 87 | 0.160 |
Why?
|
| Aged, 80 and over | 10 | 2017 | 6597 | 0.160 |
Why?
|
| Eye Diseases, Hereditary | 1 | 1999 | 32 | 0.160 |
Why?
|
| Acute Disease | 3 | 2007 | 1110 | 0.150 |
Why?
|
| Animals | 12 | 2010 | 34206 | 0.150 |
Why?
|
| Postoperative Period | 2 | 2009 | 334 | 0.150 |
Why?
|
| Fundus Oculi | 3 | 2019 | 64 | 0.140 |
Why?
|
| RNA, Messenger | 1 | 2004 | 2820 | 0.140 |
Why?
|
| Adult | 13 | 2019 | 29624 | 0.140 |
Why?
|
| Half-Life | 2 | 2008 | 158 | 0.140 |
Why?
|
| Intraocular Pressure | 2 | 2008 | 144 | 0.130 |
Why?
|
| Rats, Sprague-Dawley | 3 | 2004 | 1241 | 0.130 |
Why?
|
| Choroidal Neovascularization | 2 | 2008 | 28 | 0.130 |
Why?
|
| Middle Aged | 12 | 2019 | 26922 | 0.120 |
Why?
|
| Voriconazole | 3 | 2004 | 35 | 0.120 |
Why?
|
| Antibodies, Monoclonal, Humanized | 2 | 2011 | 512 | 0.120 |
Why?
|
| Exudates and Transudates | 3 | 2011 | 21 | 0.120 |
Why?
|
| Birth Weight | 2 | 2006 | 345 | 0.120 |
Why?
|
| Blindness | 2 | 2008 | 71 | 0.110 |
Why?
|
| Case-Control Studies | 3 | 2015 | 3299 | 0.110 |
Why?
|
| Combined Modality Therapy | 2 | 2008 | 1239 | 0.110 |
Why?
|
| Thrombolytic Therapy | 1 | 2015 | 215 | 0.100 |
Why?
|
| Rats | 3 | 2004 | 3717 | 0.100 |
Why?
|
| Pulmonary Embolism | 1 | 2015 | 177 | 0.100 |
Why?
|
| Resuscitation | 1 | 2015 | 249 | 0.100 |
Why?
|
| Administration, Oral | 3 | 2004 | 684 | 0.100 |
Why?
|
| Dose-Response Relationship, Drug | 3 | 2006 | 1698 | 0.100 |
Why?
|
| Bevacizumab | 2 | 2011 | 64 | 0.090 |
Why?
|
| Central Serous Chorioretinopathy | 1 | 2011 | 6 | 0.090 |
Why?
|
| Drug Therapy, Combination | 2 | 2008 | 1169 | 0.090 |
Why?
|
| Child, Preschool | 4 | 2012 | 13984 | 0.090 |
Why?
|
| Emergency Medical Services | 1 | 2015 | 396 | 0.090 |
Why?
|
| Heart Arrest | 1 | 2015 | 353 | 0.090 |
Why?
|
| Echinocandins | 1 | 2010 | 44 | 0.080 |
Why?
|
| Incidence | 3 | 2007 | 3137 | 0.080 |
Why?
|
| Bacteria | 2 | 2005 | 484 | 0.080 |
Why?
|
| Critical Care | 1 | 2015 | 657 | 0.080 |
Why?
|
| Child | 6 | 2019 | 24356 | 0.080 |
Why?
|
| Sulfur Hexafluoride | 1 | 2008 | 4 | 0.080 |
Why?
|
| Epiretinal Membrane | 1 | 2008 | 15 | 0.080 |
Why?
|
| Biometry | 1 | 2009 | 136 | 0.080 |
Why?
|
| Time Factors | 4 | 2019 | 6327 | 0.080 |
Why?
|
| Vancomycin | 2 | 2008 | 218 | 0.070 |
Why?
|
| Intraoperative Care | 1 | 2008 | 105 | 0.070 |
Why?
|
| Trimethoprim, Sulfamethoxazole Drug Combination | 1 | 2008 | 42 | 0.070 |
Why?
|
| Eye | 1 | 2009 | 227 | 0.070 |
Why?
|
| Risk Factors | 4 | 2007 | 10282 | 0.070 |
Why?
|
| Posture | 1 | 2008 | 154 | 0.070 |
Why?
|
| Ceftazidime | 1 | 2008 | 45 | 0.070 |
Why?
|
| Crack Cocaine | 1 | 2007 | 5 | 0.070 |
Why?
|
| Citrus | 1 | 2007 | 6 | 0.070 |
Why?
|
| Diagnosis, Differential | 2 | 2006 | 1894 | 0.070 |
Why?
|
| Myocardial Infarction | 1 | 2015 | 1039 | 0.070 |
Why?
|
| Substance Abuse, Intravenous | 1 | 2007 | 39 | 0.070 |
Why?
|
| Laser Therapy | 1 | 2009 | 249 | 0.070 |
Why?
|
| Macular Edema | 2 | 2006 | 90 | 0.070 |
Why?
|
| Dark Adaptation | 1 | 2006 | 38 | 0.070 |
Why?
|
| Vimentin | 1 | 2007 | 66 | 0.070 |
Why?
|
| Serpins | 1 | 2006 | 27 | 0.060 |
Why?
|
| Aphakia, Postcataract | 1 | 2006 | 21 | 0.060 |
Why?
|
| Cataract | 1 | 2008 | 224 | 0.060 |
Why?
|
| Candidiasis | 1 | 2007 | 129 | 0.060 |
Why?
|
| Nerve Growth Factors | 1 | 2006 | 71 | 0.060 |
Why?
|
| Vision, Ocular | 1 | 2006 | 122 | 0.060 |
Why?
|
| Silicone Oils | 1 | 2005 | 11 | 0.060 |
Why?
|
| Photic Stimulation | 1 | 2006 | 224 | 0.060 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2008 | 294 | 0.060 |
Why?
|
| Young Adult | 3 | 2019 | 9042 | 0.060 |
Why?
|
| Bartonella henselae | 1 | 2005 | 20 | 0.060 |
Why?
|
| Prospective Studies | 4 | 2006 | 6153 | 0.060 |
Why?
|
| Florida | 1 | 2005 | 78 | 0.060 |
Why?
|
| Fluorocarbons | 1 | 2005 | 56 | 0.060 |
Why?
|
| Cocaine-Related Disorders | 1 | 2007 | 203 | 0.060 |
Why?
|
| Retinal Degeneration | 1 | 2006 | 93 | 0.060 |
Why?
|
| Neuroglia | 1 | 2007 | 204 | 0.060 |
Why?
|
| Photography | 1 | 2005 | 95 | 0.060 |
Why?
|
| Eye Proteins | 1 | 2006 | 218 | 0.060 |
Why?
|
| Ophthalmic Solutions | 1 | 2004 | 91 | 0.060 |
Why?
|
| Porphyrins | 1 | 2003 | 17 | 0.050 |
Why?
|
| Blotting, Northern | 1 | 2004 | 261 | 0.050 |
Why?
|
| Photosensitizing Agents | 1 | 2003 | 34 | 0.050 |
Why?
|
| Coloring Agents | 1 | 2003 | 77 | 0.050 |
Why?
|
| Gases | 1 | 2003 | 16 | 0.050 |
Why?
|
| Indocyanine Green | 1 | 2003 | 55 | 0.050 |
Why?
|
| Antibodies, Bacterial | 1 | 2005 | 389 | 0.050 |
Why?
|
| Vancomycin Resistance | 1 | 2003 | 21 | 0.050 |
Why?
|
| In Situ Hybridization | 1 | 2004 | 471 | 0.050 |
Why?
|
| Enterococcus faecium | 1 | 2003 | 17 | 0.050 |
Why?
|
| Immunohistochemistry | 1 | 2007 | 1696 | 0.050 |
Why?
|
| Macrophages | 1 | 2007 | 620 | 0.050 |
Why?
|
| Drug Resistance, Bacterial | 1 | 2005 | 364 | 0.050 |
Why?
|
| Necrosis | 1 | 2003 | 206 | 0.050 |
Why?
|
| Spherocytes | 1 | 2002 | 2 | 0.050 |
Why?
|
| Scleral Buckling | 1 | 2002 | 13 | 0.050 |
Why?
|
| Lens Subluxation | 1 | 2002 | 4 | 0.050 |
Why?
|
| Genetic Vectors | 1 | 2006 | 937 | 0.050 |
Why?
|
| Genetic Therapy | 1 | 2006 | 687 | 0.050 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2004 | 584 | 0.050 |
Why?
|
| Hematologic Diseases | 1 | 2002 | 79 | 0.040 |
Why?
|
| Corneal Injuries | 1 | 2001 | 28 | 0.040 |
Why?
|
| Debridement | 1 | 2001 | 89 | 0.040 |
Why?
|
| Hemoglobins | 1 | 2002 | 310 | 0.040 |
Why?
|
| Intravitreal Injections | 2 | 2011 | 146 | 0.040 |
Why?
|
| Mycosis Fungoides | 1 | 2000 | 14 | 0.040 |
Why?
|
| Eye Neoplasms | 1 | 2000 | 50 | 0.040 |
Why?
|
| Cataract Extraction | 1 | 2002 | 216 | 0.040 |
Why?
|
| Ophthalmology | 1 | 2002 | 198 | 0.040 |
Why?
|
| Microphthalmos | 1 | 1999 | 60 | 0.040 |
Why?
|
| Bacteremia | 1 | 2003 | 406 | 0.040 |
Why?
|
| Hyperplasia | 1 | 1999 | 208 | 0.040 |
Why?
|
| Device Removal | 1 | 2000 | 221 | 0.040 |
Why?
|
| Adolescent | 2 | 2019 | 19328 | 0.040 |
Why?
|
| Biomarkers | 1 | 2007 | 3081 | 0.040 |
Why?
|
| Infarction | 1 | 2017 | 23 | 0.030 |
Why?
|
| Texas | 1 | 2005 | 3586 | 0.030 |
Why?
|
| Macula Lutea | 1 | 2017 | 45 | 0.030 |
Why?
|
| Giant Cell Arteritis | 1 | 2017 | 58 | 0.030 |
Why?
|
| Infant | 2 | 2012 | 12462 | 0.030 |
Why?
|
| Germany | 1 | 2015 | 65 | 0.030 |
Why?
|
| Ultrasonography | 1 | 1999 | 940 | 0.030 |
Why?
|
| Vitreous Hemorrhage | 2 | 2005 | 9 | 0.030 |
Why?
|
| Skin Neoplasms | 1 | 2000 | 862 | 0.020 |
Why?
|
| Subretinal Fluid | 1 | 2011 | 11 | 0.020 |
Why?
|
| Hemorrhage | 1 | 2015 | 469 | 0.020 |
Why?
|
| Internship and Residency | 1 | 2002 | 1181 | 0.020 |
Why?
|
| T-Lymphocytes | 1 | 2000 | 1718 | 0.020 |
Why?
|
| Lipopeptides | 1 | 2010 | 33 | 0.020 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2010 | 154 | 0.020 |
Why?
|
| Survival Rate | 1 | 2015 | 2057 | 0.020 |
Why?
|
| Mice, Inbred C57BL | 2 | 2010 | 4403 | 0.020 |
Why?
|
| Retinal Ganglion Cells | 1 | 2010 | 99 | 0.020 |
Why?
|
| Beverages | 1 | 2007 | 100 | 0.020 |
Why?
|
| Tonometry, Ocular | 1 | 2006 | 31 | 0.020 |
Why?
|
| Urine | 1 | 2006 | 90 | 0.020 |
Why?
|
| Cohort Studies | 1 | 2015 | 4812 | 0.020 |
Why?
|
| Sputum | 1 | 2006 | 106 | 0.020 |
Why?
|
| Models, Animal | 1 | 2006 | 464 | 0.010 |
Why?
|
| Fungi | 1 | 2004 | 69 | 0.010 |
Why?
|
| Biological Transport | 1 | 2004 | 355 | 0.010 |
Why?
|
| Eye Enucleation | 1 | 2003 | 54 | 0.010 |
Why?
|
| Adenoviridae | 1 | 2006 | 604 | 0.010 |
Why?
|
| Cryosurgery | 1 | 2002 | 47 | 0.010 |
Why?
|
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 1 | 2002 | 97 | 0.010 |
Why?
|
| Mice | 2 | 2010 | 17621 | 0.010 |
Why?
|
| Fatal Outcome | 1 | 2002 | 357 | 0.010 |
Why?
|
| Choroid Neoplasms | 1 | 2000 | 25 | 0.010 |
Why?
|
| Optic Nerve Neoplasms | 1 | 2000 | 19 | 0.010 |
Why?
|
| Thrombocytopenia | 1 | 2002 | 224 | 0.010 |
Why?
|
| Immunophenotyping | 1 | 2000 | 329 | 0.010 |
Why?
|
| Reoperation | 1 | 2002 | 833 | 0.010 |
Why?
|
| Flow Cytometry | 1 | 2000 | 794 | 0.010 |
Why?
|
| Clinical Competence | 1 | 2002 | 1003 | 0.010 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2000 | 1252 | 0.010 |
Why?
|